Literature DB >> 28798520

Suvorexant.

.   

Abstract

Entities:  

Year:  2017        PMID： 28798520      PMCID： PMC5478396          DOI： 10.18773/austprescr.2017.040

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  4 in total

1.  Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

Authors:  David Michelson; Ellen Snyder; Erin Paradis; Mary Chengan-Liu; Duane B Snavely; Jill Hutzelmann; James K Walsh; Andrew D Krystal; Ruth M Benca; Martin Cohn; Christopher Lines; Thomas Roth; W Joseph Herring
Journal:  Lancet Neurol       Date:  2014-03-27       Impact factor: 44.182

Review 2.  Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

Authors:  L Citrome
Journal:  Int J Clin Pract       Date:  2014-09-18       Impact factor: 2.503

3.  Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.

Authors:  W Joseph Herring; Kathryn M Connor; Neely Ivgy-May; Ellen Snyder; Ken Liu; Duane B Snavely; Andrew D Krystal; James K Walsh; Ruth M Benca; Russell Rosenberg; R Bart Sangal; Kerry Budd; Jill Hutzelmann; Heather Leibensperger; Samar Froman; Christopher Lines; Thomas Roth; David Michelson
Journal:  Biol Psychiatry       Date:  2014-10-23       Impact factor: 13.382

4.  Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.

Authors:  W Joseph Herring; Ellen Snyder; Kerry Budd; Jill Hutzelmann; Duane Snavely; Kenneth Liu; Christopher Lines; Thomas Roth; David Michelson
Journal:  Neurology       Date:  2012-11-28       Impact factor: 9.910
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.